Research, Development, And Testing Services - Insider Trading Data

Insiders are officers, directors, or significant investors. This page shows insider sentiment and transactions for the Research, industry. Research shows that insider trades are predictive of future stock returns. By examining insider trades for an industry, we can understand what well-informed people think of the overall future industry prospects.

Research, Development, And Testing Services - Insider Buy/Sell Ratio

Insider selling and buying is a useful indicator for analyzing the market because it serves as a proxy for their optimism or pessimism in their own companies. By looking at ratio of total selling and buying across the entire market, we might be able to draw some conclusions about the future market.

We offer two charts here. The first one shows the total dollar volume of buying and selling by insiders. The second chart shows the ratio of the number of insiders selling, vs. the number of insiders buying. In both charts, we filter out trades made by indirect holders (such as trusts), and 10% owners (who, although considered an 'insider' by the SEC, do not actually manage the companies in which they are considered insiders).

Corporate Insider Buy Sell Ratio (Dollar Volume) - Research, Development, And Testing Services
Corporate Insider Buy Sell Ratio (Insider Count) - Research, Development, And Testing Services
Research, Development, And Testing Services - Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b5-1 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Security Form Insider Code 10b5-1 Direct Share
Price
Shares
Changed
2025-02-28 ABSI / Absci Corporation 4 Jonasson Zachariah F - Taxes D 4.04 -5,219
2025-02-27 MEDP / Medpace Holdings, Inc. 4 EWALD STEPHEN P P - Purchase D 326.11 2
2025-02-26 INCY / Incyte Corporation 4 Denton Sheila A. S - Sale D 74.08 -4,495
2025-02-26 INCY / Incyte Corporation 4 Denton Sheila A. S - Sale D 74.07 -9,574
2025-02-26 INCY / Incyte Corporation 4 Denton Sheila A. M - Exercise D 58.06 9,574
2025-02-25 CRL / Charles River Laboratories International, Inc. 4 Girshick Birgit G - Gift D -430
2025-02-24 MEDP / Medpace Holdings, Inc. 4 Carley Brian T S - Sale D 345.59 -4,003
2025-02-24 MEDP / Medpace Holdings, Inc. 4 Carley Brian T M - Exercise D 42.62 8,127
2025-02-23 NEO / NeoGenomics, Inc. 4 Smith Christopher M M - Exercise D 57,413
2025-02-23 NEO / NeoGenomics, Inc. 4 Harris Melody M - Exercise D 8,443
2025-02-23 NEO / NeoGenomics, Inc. 4 Stone Warren M - Exercise D 8,443
2025-02-23 NEO / NeoGenomics, Inc. 4 Sherman Jeffrey Scott M - Exercise D 15,535
2025-02-23 NEO / NeoGenomics, Inc. 4 Olivo Alicia C M - Exercise D 8,443
2025-02-23 NEO / NeoGenomics, Inc. 4 Sherman Jeffrey Scott F - Taxes D -4,207
2025-02-23 NEO / NeoGenomics, Inc. 4 Olivo Alicia C F - Taxes D -2,504
2025-02-23 NEO / NeoGenomics, Inc. 4 Smith Christopher M F - Taxes D -14,067
2025-02-23 NEO / NeoGenomics, Inc. 4 Stone Warren F - Taxes D -2,472
2025-02-23 NEO / NeoGenomics, Inc. 4 Harris Melody F - Taxes D -2,056
2025-02-20 CRL / Charles River Laboratories International, Inc. 4 LaPlume Joseph W S - Sale D 162.50 -4,400
2025-02-20 CRL / Charles River Laboratories International, Inc. 4 FOSTER JAMES C P - Purchase D 165.01 6,075
2025-02-20 CRL / Charles River Laboratories International, Inc. 4 Girshick Birgit P - Purchase D 164.63 1,514
2025-02-19 OABI / OmniAb, Inc. 4 FOEHR MATTHEW W S - Sale D 3.67 -19,522
2025-02-19 OABI / OmniAb, Inc. 4 Berkman Charles S S - Sale D 3.67 -7,255
2025-02-19 OABI / OmniAb, Inc. 4 GUSTAFSON KURT A S - Sale D 3.67 -7,255
2025-02-18 OABI / OmniAb, Inc. 4 FOEHR MATTHEW W S - Sale D 3.68 -13,964
2025-02-18 NOTV / Inotiv, Inc. 4 Freeman Jeffrey Brennan S - Sale D 4.0450 -1,339
2025-02-18 OABI / OmniAb, Inc. 4 Berkman Charles S S - Sale D 3.68 -8,215
2025-02-18 NOTV / Inotiv, Inc. 4 Taylor Beth S - Sale D 4.0061 -4,370
2025-02-18 NOTV / Inotiv, Inc. 4 Leasure Robert Jr. S - Sale D 3.8189 -73,617
2025-02-18 NOTV / Inotiv, Inc. 4 Sagartz John E S - Sale D 3.9357 -2,113
2025-02-16 OABI / OmniAb, Inc. 4 GUSTAFSON KURT A M - Exercise D 13,541
2025-02-16 OABI / OmniAb, Inc. 4 FOEHR MATTHEW W M - Exercise D 36,458
2025-02-16 OABI / OmniAb, Inc. 4 Berkman Charles S M - Exercise D 13,541
2025-02-15 OABI / OmniAb, Inc. 4 FOEHR MATTHEW W M - Exercise D 26,549
2025-02-15 OABI / OmniAb, Inc. 4 Berkman Charles S M - Exercise D 15,615
2025-02-10 IQV / IQVIA Holdings Inc. 4 BOUSBIB ARI M - Exercise D 65.16 40,000
2025-02-10 IQV / IQVIA Holdings Inc. 4 BOUSBIB ARI F - Taxes D 206.97 -3,335
2025-02-10 IQV / IQVIA Holdings Inc. 4 Bruehlman Ronald E F - Taxes D 206.97 -907
2025-02-10 IQV / IQVIA Holdings Inc. 4 Patel Bhavik F - Taxes D 206.97 -108
2025-02-10 IQV / IQVIA Holdings Inc. 4 Cherofsky Keriann F - Taxes D 206.97 -16
2025-02-10 IQV / IQVIA Holdings Inc. 4 STAUB W RICHARD F - Taxes D 206.97 -141
2025-02-10 IQV / IQVIA Holdings Inc. 4 Sherbet Eric F - Taxes D 206.97 -179
2025-02-10 IQV / IQVIA Holdings Inc. 4 BOUSBIB ARI D - Sale to Issuer D 206.97 -26,585
2025-02-03 NOTV / Inotiv, Inc. 4 Krupp Jeffrey Arthur S - Sale D 4.1800 -472
2025-02-01 ABSI / Absci Corporation 4 McClain Sean F - Taxes D 3.71 -16,991
2025-02-01 ABSI / Absci Corporation 4 Jonasson Zachariah F - Taxes D 3.71 -11,567
2025-02-01 ABSI / Absci Corporation 4 Busch Andreas F - Taxes D 3.71 -1,469
2025-02-01 ABSI / Absci Corporation 4 Bedrick Todd F - Taxes D 3.71 -2,630
2025-01-31 NOTV / Inotiv, Inc. 4 Taylor Beth S - Sale D 4.465 -2,054
2025-01-31 NOTV / Inotiv, Inc. 4 Sagartz John E S - Sale D 4.4754 -2,118
P
Pembelian sekuritas non-derivatif atau derivatif di pasar terbuka atau secara pribadi.
S
Penjualan terbuka atau penjualan pribadi atas sekuritas non-derivatif atau derivatif.
A
Hibah, penghargaan, atau perolehan sekuritas lainnya dari perusahaan (seperti opsi)
C
Konversi turunan
D
Penjualan atau pengalihan sekuritas kembali ke perusahaan.
F
Pembayaran harga pelaksanaan atau kewajiban pajak menggunakan sebagian sekuritas yang diterima dari perusahaan.
G
Pemberian sekuritas oleh atau kepada orang dalam.
K
Swap ekuitas dan transaksi lindung nilai serupa
M
Pelaksanaan atau konversi sekuritas derivatif yang diterima dari perusahaan (seperti opsi)
V
Transaksi yang dilaporkan secara sukarela pada Formulir 4.
J
Lainnya (disertai dengan catatan kaki yang menjelaskan transaksi tersebut)